Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma
Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma
复制标题
DOI：
10.1158/1078-0432.ccr-07-1032
复制
发表时间：
2008-01-15
影响因子：
11.5
通讯作者：
Wu, Ming-Shiang
中科院分区：
文献类型：
--
作者：
Liao, Wei-Chih;Lin, Jaw-Town;Wu, Ming-Shiang
目的：白细胞介素-6（IL-6）是判断胃癌患者生存的一个预后指标，但这一点尚未得到生存分析的证实。在亚洲人中，-6346等位基因与IL-6产生增加相关。本研究的目的是评估血清IL-6水平，-634G/C多态性，胃癌切除术后的总生存率之间的关联。实验设计：共155例连续胃癌患者进行了评价。采用酶联免疫吸附试验分析血清IL-6水平。PCR和限制性片段长度多态性分析确定基因型。结果：血清IL-6水平与患者年龄、临床分期有关，而与-634G/C基因型无关。在低分化胃癌患者中，II期或III期胃癌患者的中位生存期为1，418天。（13 pg/mL是生存率差的重要预测因子（风险比，1.77; 95%置信区间，1.07-2.92; P = 0.026）。血清IL-6水平>13 pg/mL与肿瘤进展相关，并且是切除术后生存不良的独立预测因子。在II、III期胃癌患者中，血清IL-6水平作为预后指标比分期更有效。通过测量IL-6，这些患者可以分为两组，生存率有显著差异。-634G/C多态性与血清IL-6水平和生存期无关。
Purpose: It has been suggested that interleukin-6 (IL-6) is a prognostic indicator for survival in patients with gastric carcinoma, but this has not been proved using survival analysis. In Asians, the -6346 allele is associated with increased IL-6 production. The objective of this study was to evaluate the association between serum IL-6 levels, -634G/C polymorphism, and overall survival after resection for gastric carcinoma.Experimental Design: A total of 155 consecutive patients with gastric carcinoma were evaluated. Serum IL-6 levels were analyzed using an enzyme-linked immunoabsorbent assay. Genotype was determined by PCR and restriction fragment length polymorphism. Serum levels and survival were correlated with genotype and clinicopathologic factors.Results: Age and stage, but not -634G/C genotype, were associated with serum IL-6 levels. The median survival for patients with stage II or stage III gastric carcinoma was 1,418 days in patients with low (13 pg/mL was a significant predictor of poor survival (hazard ratio, 1.77; 95% confidence interval, 1.07-2.92; P = 0.026).Conclusions: Serum IL-6 level of >13 pg/mL correlates with tumor progression and is an independent predictor of poor survival after resection. In patients with stage II and III gastric carcinoma, serum IL-6 level is more effective than stage as a prognostic indicator. By measuring IL-6, these patients can be divided into two groups with significant differences in survival. The -634G/C polymorphism is not associated with serum IL-6 level or survival.